Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...
In a deputation to council on Monday, the organizers of last summer’s Autofest car show at Elgin Park said the event “put Uxbridge on the map as the hot rod centre of Ontario.” ...
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...
UXBRIDGE ― Uxbridge Superintendent Michael Baldassarre was placed on paid administrative leave and an interim superintendent was named during a School Committee meeting Tuesday night ...
The superintendent of Uxbridge Public Schools is on paid administrative leave as of Tuesday night in connection with an arrest stemming from an OUI incident last week, the Telegram & Gazette reported.
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine … ...
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities ...
The superintendent of Uxbridge Public Schools appeared in court Tuesday after he was arrested for allegedly driving while intoxicated over the weekend, according to court records. Michael ...
Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback